Aletheia Capital Endeavours Launches RepIntel, a Campaign-Grade Platform to Accelerate Global Access to Therapies

RepIntel reimagines pharmaceutical outreach as a core layer of global health infrastructure, converting field operations into a responsive intelligence network that channels lifesaving therapies to the patients and populations who need them most.

New York, NY, United States, October 17, 2025 -- Aletheia Capital Endeavours (ACE) today announced the launch of RepIntel, a precision field-intelligence platform designed to close one of healthcare’s most persistent gaps: the failure of lifesaving therapies to reach the patients they were created for. 

The company was founded by Gavin Perri, the New York impresario and Executive Chairman of Aletheia Capital Endeavours, and Filomena Di Luise, Senior Executive Manager at a Fortune 100 technology firm, who will serve as President and Chief Operating Officer for RepIntel. Di Luise brings enterprise-scale infrastructure expertise to the venture's leadership team. 

Drawing on frameworks that redefined political mobilization, RepIntel translates those same principles of precision targeting, coordinated field orchestration, and real-time intelligence into the final mile of healthcare delivery. 

"Every year, scientific breakthroughs transform what medicine can do. Yet millions still go without the treatments that could change or save their lives," said Gavin Perri, Executive Chairman of Aletheia Capital Endeavours. "RepIntel is designed to solve that systemic failure. By transforming field operations into an adaptive intelligence network, we’re building the connective tissue that allows innovation to translate into real-world impact." 

RepIntel unites vast healthcare datasets with ground-level decision-making, enabling pharmaceutical teams to identify unmet needs, prioritize underserved populations, and orchestrate outreach with surgical precision. Its first deployments target highly regulated markets, where the speed, accuracy, and equity of distribution directly determine patient outcomes. 

The launch marks ACE’s first flagship technology venture and reflects a broader thesis: that the most resilient and equitable healthcare systems will be those that harness distributed intelligence, empowering those closest to patients to guide the flow of treatments and resources in real time. In doing so, RepIntel establishes the operational layer needed to ensure that scientific progress becomes societal progress.

About the company: About Aletheia Capital Endeavours:Aletheia Capital Endeavours (ACE) is a New York-based venture studio and applied thinktank architecting the cultural, technological, and intellectual systems that shape thefuture. Its work spans entertainment ventures and large-scale philanthropic initiatives,often structured as thesis-oriented coalitions of high-net-worth partners that align socialimpact with strategic tax efficiency and legacy-oriented wealth planning.About RepIntel:RepIntel is a precision field-intelligence platform incubated by ACE, designed as a criticallayer in the delivery architecture of modern healthcare. It enables pharmaceutical andhealthcare institutions to deploy campaign-grade targeting, adaptive outreach, anddistributed decision-making to bridge the last-mile gap, ensuring that medicalbreakthroughs reach patients with the speed, precision, and equity the 21st centurydemands.

Contact Info:
Name: Public Relations
Email: Send Email
Organization: Aletheia Capital Endeavours
Website: https://www.repintel.com

Release ID: 89172719

Should any errors, concerns, or inconsistencies arise from the content provided in this press release that require attention or if a press release needs to be taken down, we kindly request that you immediately contact us at error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our efficient team will be at your disposal for timely assistance within 8 hours – taking necessary measures to rectify identified issues or providing guidance on the removal process. We prioritize delivering accurate and reliable information.